Top
This page is only for information of and use by registered medical practitioners. Other persons are advised not to act on the basis of information contained in this page. They are requested to consult registered medical practitioner.

Nicardia Retard (Nifedipine Extended release Tablet) is used for the prophylaxis of chronic stable angina pectoris and the treatment of hypertension. It comes in two doses Nicardia Retard 10mg and Nicardia Retard 20mg. It is Manufactured by J. B. CHEMICALS & PHARMACEUTICALS LTD.


Nifedipine is a specific and potent calcium antagonist of the 1, 4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell.


Nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. In hypertension, the main action of Nifedipine retard is to cause peripheral vasodilatation and thus reduce peripheral resistance. In angina, Nifedipine retard reduces peripheral and coronary vascular resistance, leading to an increase in coronary blood flow, cardiac output and stroke volume, whilst decreasing after-load. Additionally, nifedipine dilates submaximally both clear and atherosclerotic coronary arteries, thus protecting the heart against coronary artery spasm and improving perfusion to the ischaemic myocardium.

Nifedipine reduces the frequency of painful attacks and the ischaemic ECG changes irrespective of the relative contribution from coronary artery spasm or atherosclerosis. After oral administration nifedipine is rapidly and almost completely absorbed, for further information (See product Leaflet).

Overview
Name of Product: NICARDIA RETARD 10/20
Marketed by : JB Chemicals and Pharmaceuticals Ltd
Medicine composition: Nifedipine IP - 10 mg/ 20mg
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Tablets

For the prophylaxis of chronic stable angina pectoris and the treatment of hypertension.

The recommended starting dose of Nifedipine retard is 10 mg every 12 hours swallowed with water with subsequent titration of dosage according to response. Nifedipine retard tablets permit titration of the initial dosage, which may be adjusted to 40 mg every 12 hours, to a maximum daily dose of 80 mg. (See product Leaflet )

Nifedipine retard must not be administered to patients:

  • Known hypersensitivity to the active substance, or to other dihydropyridine .
  • In cases of cardiogenic shock, clinically significant aortic stenosis, unstable angina, or during or within 4 weeks of a myocardial infarction.
  • For the treatment of acute attacks of angina. The safety of Nifedipine retard in malignant hypertension has not been established.
  • For secondary prevention of myocardial infarction
  • It should not be administered concomitantly with rifampicin. For further information.(See Product Leaflet)
  • Nifedipine retard is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal.
  • Care must be exercised in patients with very low blood pressure (severe hypotension with systolic pressure less than 90 mm Hg).
  • Nifedipine retard is not recommended for use during breast-feeding.
  • In patients with mild, moderate or severe impaired liver function, careful monitoring and a dose reduction may be necessary.
  • Medicinal product contains lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
  • Nifedipine retard should be used with caution in patients whose cardiac reserve is poor.
  • For use in pregnancy, advised only when clinical conditions of the woman require treatment with Nifedipine.

For further information Download the product Leaflet.

Information for Patients: Nifedipine Extended Release Tablets should be swallowed whole. Do not chew, divide or crush tablets. Do not be concerned if you occasionally notice in your stool something that looks like a tablet. In Nifedipine Extended Release Tablets, the medication is contained within a non-absorbable shell that has been specially designed to slowly release the drug for your body to absorb. When this process is completed, the empty tablet is eliminated from your body.

Download the Product Leaflet, to see the detailed drug interactions.

Download the Product Leaflet, to see the the detailed information on the Undesirable Side effects/ Overdose.

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties of Nicardia Retard.

Contact us for further information

Nicardia Retard (Nifedipine Extended release Tablet) is used for the prophylaxis of chronic stable angina pectoris and the treatment of hypertension. It comes in two doses Nicardia Retard 10mg and Nicardia Retard 20mg. It is Manufactured by J. B. CHEMICALS & PHARMACEUTICALS LTD.


Nifedipine is a specific and potent calcium antagonist of the 1, 4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell.


Nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. In hypertension, the main action of Nifedipine retard is to cause peripheral vasodilatation and thus reduce peripheral resistance. In angina, Nifedipine retard reduces peripheral and coronary vascular resistance, leading to an increase in coronary blood flow, cardiac output and stroke volume, whilst decreasing after-load. Additionally, nifedipine dilates submaximally both clear and atherosclerotic coronary arteries, thus protecting the heart against coronary artery spasm and improving perfusion to the ischaemic myocardium.

Nifedipine reduces the frequency of painful attacks and the ischaemic ECG changes irrespective of the relative contribution from coronary artery spasm or atherosclerosis. After oral administration nifedipine is rapidly and almost completely absorbed, for further information (See product Leaflet).

ARTICLE UPDATE


• Hypertension and Pregnancy

• Hypertension in Pregnancy Guidelines (2018)

• NIFEDIPINE in PREECLAMPSIA.

The above page is meant only for the registered medical practitioner or a hospital or a laboratory only. The information here is not for the general public. Any content/information on this page and Medical Dialogues website, in general, does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Information on this site is meant for physician and healthcare professional's awareness and Medical Dialogues does not recommend or endorse any specific drugs, tests, physicians, products, procedures, opinions, "off-label" drug uses or other information that may be mentioned on the Site. Do not self-medicate if you are not a doctor. Use of this site and this webpage is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here.

© 2020 Medical Dialogues, All rights reserved.
X
X